Viewing Study NCT00621361


Ignite Creation Date: 2025-12-24 @ 11:55 AM
Ignite Modification Date: 2026-03-11 @ 10:32 AM
Study NCT ID: NCT00621361
Status: COMPLETED
Last Update Posted: 2012-12-17
First Post: 2008-02-12
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module